Clinical Trial · NCT03996850

SPECT/CT for the Characterization of Renal Masses

Overview

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Contacts

Brian Shuch (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03996850

Drug / Compound

sestamibi

Isotope(s):

Target(s):

Mitochondria-Targeting Moieties

Ligand Class: Small Molecules

Eligibility

Inclusion

New diagnosis of a renal tumor (within past 3 months).
Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
Life expectancy (\> 1 year).
* Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).

Exclusion

Presence of an active, untreated, non-renal malignancy.
History of bleeding diathesis or recent bleeding episode.
A prior needle biopsy of the mass resulting in histologic diagnosis.
* Presence of multiple solid renal tumors.
A prior diagnosis of kidney cancer.

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…